InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,618.26
(
-0.29%
)
US TECH 100
18,857.60
(
0.00%
)
Dow Jones
41,503.10
(
-0.25%
)
Brent Oil
73.98
(
2.20%
)
Bitcoin
62,106.91
(
0.71%
)
Post# of 253152
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 840
Posts 120462
Boards Moderated 18
Alias Born 09/05/2002

DewDiligence

Member Level

Re: glass_half_full post# 204611

Monday, 09/26/2016 10:04:39 AM

Monday, September 26, 2016 10:04:39 AM

Post# of 253152

This would allow biotech investors to develop their own portfolios of single-drug cash flow streams rather than being forced to accept the ad hoc portfolios that big pharma have built over the years.

I don't follow how splitting up companies would enable investors to obtain such flexibility—please elaborate.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up